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Abstract
In normal mice, the lentiviral vector (LV) is very efficient to target the RPE cells, but transduces retinal neurons well only
during development. In the present study, the tropism of LV has been investigated in the degenerating retina of mice,
knowing that the retina structure changes during degeneration. We postulated that the viral transduction would be
increased by the alteration of the outer limiting membrane (OLM). Two different LV pseudotypes were tested using the
VSVG and the Mokola envelopes, as well as two animal models of retinal degeneration: light-damaged Balb-C and
Rhodopsin knockout (Rho-/-) mice. After light damage, the OLM is altered and no significant increase of the number of
transduced photoreceptors can be obtained with a LV-VSVG-Rhop-GFP vector. In the Rho-/- mice, an alteration of the OLM
was also observed, but the possibility of transducing photoreceptors was decreased, probably by ongoing gliosis. The use
of a ubiquitous promoter allows better photoreceptor transduction, suggesting that photoreceptor-specific promoter
activity changes during late stages of photoreceptor degeneration. However, the number of targeted photoreceptors
remains low. In contrast, LV pseudotyped with the Mokola envelope allows a wide dispersion of the vector into the retina
(corresponding to the injection bleb) with preferential targeting of Mu ¨ller cells, a situation which does not occur in the wild-
type retina. Mokola-pseudotyped lentiviral vectors may serve to engineer these glial cells to deliver secreted therapeutic
factors to a diseased area of the retina.
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Introduction
Research in gene therapy for eye diseases has become
increasingly interesting with the development of vectors efficient
in targeting different cell types of the retina or the cornea. Among
different vector families, the AAV vectors and the lentiviral vectors
are widely used for either a gene replacement or a neuroprotective
strategy. Depending on the serotype, AAV vectors can preferen-
tially target the retinal pigmented epithelium (RPE[1,2]), or
photoreceptors[3,4], whereas lentiviral vectors predominantly
transduce the RPE cells[5,6] and Mu ¨ller cells at the injection
site[7]. AAV-based gene therapy has shown many successes in
gene replacement treatments for animal models of autosomal
inherited retinal degeneration[8], whereas the HIV1-derived
lentiviral vectors (LVs) were efficient against diseases affecting
the RPE[1,9–11], in retinal ganglion cells when injured[12], and
in photoreceptors when the cells are targeted early during
development[13]. Indeed, the HIV1-derived lentiviral vector can
target photoreceptors just after birth and some days later when no
physical barrier is formed yet between the RPE and the
photoreceptors, and, between photoreceptors themselves[14].
The equine lentiviral vector seems to have the same behaviour,
with a slightly increased capacity to transduce photorecep-
tors[15,16], still improved using the Rabbies-G envelope[15].
Most of the studies on vector tropism were undertaken in
normal retinas or at an early stage of retinal degeneration and little
is known concerning the ability of the vectors to transduce retinal
cells at advanced stages of retinal degeneration. During disease
progression, the retina undergoes a major structural remodelling,
thus creating a different environment that may impact vector
diffusion and transduction capabilities. Indeed, the retina shows
important changes in neurons[17,18] and glia such as gliosis,
rupture of the outer limiting membrane[19,20] (OLM), cell loss,
and remodelling of synaptic connexions (for review[21]). These
retinal modifications were mainly studied with the goal of
improving cell integration after transplantation into the retina.
Cell transplantation studies revealed that the OLM and extracel-
lular matrix proteins impair the passage of cells from the subretinal
space towards the inner retina [22,23]. For instance, the loss of the
Crumb protein which participates to the cohesion of the OLM,
facilitates the migration of transplanted primary retinal cells into
the outer nuclear layer[22]. Concerning gene transfer, a recent
interesting work shows that, after intravitreal injection, a Cy3-
labelled-AAV vector diffuses into the retina of a rat model of
retinal degeneration, whereas no diffusion into this tissue was
observed in wild-type animals. Moreover, cells of all layers,
including photoreceptors can be targeted, the efficiency remaining
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cells, when the structural change of the inner-limiting membrane
occurs during retinal disease, [24].
Hypothesizing that the structural remodelling taking place
during the course of retinal degeneration could limit the barrier
mechanism, we have investigated in the present study whether
HIV1-derived lentiviral vectors have a capacity to diffuse through
retinal layers and transduce various cell types when injected into
degenerating retinas. We focused our study on two different
animal models of photoreceptor loss, one acutely induced, the light
damage model, the other modelling an inherited disease, the
Rhodopsin knockout mouse (Rho-/-). These experiments were
performed using HIV1-derived vectors pseudotyped with the
pantropic vesicular stomatitis virus glycoprotein (VSV-G) or the
Lyssavirus Mokola glycoprotein (Mok-G) previously shown to
preferentially target glial cells in the central nervous system[25].
Results
To investigate whether the lentiviral vector (LV) targets the
neuroretina better during retinal degeneration, we first examined
the integrity of the OLM in an acute model of retinal
degeneration, the light damage model. Mice were submitted to
5000 lux during one hour and the retina fixed 36 hours later, at
the apoptosis peak, for immunohistochemistry investigation. Zona-
occludin-1 (ZO-1) is a major component stabilizing the structure
of adherent junctions and was shown to be altered in certain
neurodegenerative processes including the Rhodopsin knockout
(Rho-/-) mouse[19,20]. ZO-1 participates to tight junctions as well
as adherent junctions and, with the help of other members of the
cadherin, catenin and occludin family members, forms a hermetic
barrier at the OLM level. These proteins are deregulated in the
Rho-/- retina [19,20]. In control mice, a linear continuous labelling
of ZO-1 can be observed at the level of the OLM (Figure 1a). In
mice subjected to light damage, several disruptions of the ZO-1
linear staining are evident in the central part of the retina with a
reduced expression (Figure 1b), but not in the periphery where no
toxic effects occur.
In consequence, in order to assess the influence of these
structural remodellings of the retina on lentiviral transduction and
diffusion, we injected groups of mice 36 hours after light damage
with a LV driving the expression of GFP under the Rhodopsin
promoter and pseudotyped with a VSVG envelope (LV-VSVG-
Rhop-GFP) to first investigate whether the photoreceptors can be
targeted in this model. The number of GFP-positive photorecep-
tors per slice was counted 7 days later. No significant differences
were observed between groups (Figure 1 c and d, controls:
71637.5 and light damage: 71622.5 GFP cells/200 mm, n=4
and 6 respectively). The rapid loss of outer segments and
photoreceptors after the light damage induction may be in part
responsible for the impaired efficacy of LV penetration into the
ONL in this model. A constant loss of photoreceptors during the
first days after light damage may have eliminated the cells that
were preferentially transduced after the OLM rupture. We also
investigated whether the OLM was reinforced by a Mu ¨ller cell
process (explaining the poor vector diffusion), but no glial cell
reaction at the ONL level was observed 36 hours after light
damage (data not shown).
We then decided to test the same vector in an animal model of
slow retinal degeneration process to avoid the problem of rapid
photoreceptor loss. The vector diffusion and transduction capacity
was investigated in young adults as well as more mature Rhodopsin
knockout mice (Rho-/-), which have no phototransduction in their
rods and show a rod loss starting at around one month. The
integrity of the OLM was first investigated, previous results having
already reported alteration of the ZO-1 localization in the Rho-/-
mouse[19,20]. At 1 and 1.4 months of age, the retinas of the
Rho-/- and wild type controls show no differences respectively,
whereas few alterations of the ZO-1 structure can be detected at
2.4 months (Figure 2e). At 4.9 months in Rho-/- retinas, ZO-1
labelling presents a multitude of discontinuous regions revealing a
profound change of the OLM structure (Figure 2f). These results
confirm previous observations[19] also showing that the integrity
of the OLM is altered in this model, although in our hands the
Rho-/- retinas show a delayed alteration of ZO-1 distribution in
the OLM. Nonetheless, our results confirm that the OLM barrier
is partially modified, potentially allowing a better diffusion of
lentiviral vectors when injected subretinally. To test this hypothesis
and to reveal transduced photoreceptors, the LV-VSVG-Rhop-
GFP was injected into young adults (1 month old), before the
disruption of the ZO-1 expression, and advanced-stage (4.9
months old) Rho-/- mice, when the OLM structure is altered, as
well as in age-matched wild type C57/Bl6 control mice (WT). In
young adult animals (Figure 3a and b), we observed retinal
transduction near the site of injection in Rho-/- or C57/Bl6 mice.
Few photoreceptors were transduced in a 200 mm longitudinal
portion of the retinal section (excluding the site of injection) of
Rho-/- or C57/Bl6 mouse retinas. No difference of transduction
was observed between Rho-/- and WT mice. In older animals (4.9
months, Figure 3d and d9), we obtained very few transduced
photoreceptors in Rho-/- mice and some transduction in WT mice.
To potentially reveal low GFP-expressing cells, we performed
immunolabeling against GFP using a secondary antibody with a
red fluorophore (Alexa633) to evidence cells not detected by GFP.
We observed that red cells were also positive for GFP. In advanced
degeneration processes (see Figure 3d), the LV-VSVG-Rhop-GFP
vector conserved the same tropism as observed after injection into
the normal retina, but with less efficiency.
Another vector bearing a ubiquitous promoter, a short fragment
of the Elongation Factor1 promoter (LV-VSVG-EFs-GFP), was
injected into the same model 1) to verify that this lack of
photoreceptor transduction was not a problem of gene expression
due to the health of the photoreceptors (decrease of rhodopsin
promoter activity for instance), and 2) to determine whether other
cell types can be reached by the vector when the OLM shows a
disruption of the ZO-1 expression. The vector was tested in late-
stage Rho-/- degenerating retinas and in age-matched WT
controls. For all animals, the largest transduced area was observed
in the RPE layer confirming previous data showing that the
lentiviral vector carrying a ubiquitous promoter targets mainly
RPE cells[5,6]. The size of the transduced region of the RPE layer
or the degenerating retinas of the Rho-/- mice was not different in
comparison to normal transduced retinas (see graph in Figure 4c).
This result shows that this vector has the same diffusion capacity in
the wild-type or the diseased retina. Interestingly, in contrast with
the control group, the Rho-/- retinas contained several GFP-
positive cells in the neuroretina (but in the injection site near the
needle tract only). We identified a significant number of GFP
positive cells in the ONL in the transduced area of aged Rho-/-
animals (Figure 4 g, h, and i, arrows), which was unexpected in
view of the results we obtained with the LV-VSVG-Rhop-GFP.
This suggests that the EFs promoter is more efficient than the
Rhodopsin promoter to drive transgene expression in the photore-
ceptors, during advanced stage of the degeneration in the Rho-/-
mice. This reduced activity of the Rhodopsin promoter may be the
consequence of the poor photoreceptor health at this stage of
degeneration in the Rho-/- mouse. We also checked whether cones
were transduced by the vector, but only a very weak expression for
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detection problematic. Nonetheless, rare cells positive for GFP and
GNAT2 were observed (data not shown) revealing that the EFs
promoter is active in cones and that GFP positive cells in the ONL
could also be cones.
Beside these photoreceptors, some of the GFP positive cells in
the INL have a Mu ¨ller cell appearance (Figure 4d and g). To
confirm that some glia cells were targeted, we performed
immunolabelling for GFAP and observed certain cells expressing
both GFP and GFAP (Figure 4h and i). In addition, the high
expression level of GFAP in the Rho-/- retina at this stage of the
degenerating process attests of a gliosis process as previously
described[22]. We also observed an increased GFAP immunola-
beling at the OLM level (Figure 4h and i) revealing an important
remodeling of this membrane during the degenerating process. A
similar gliosis was detected in the retina of another mouse model of
retinal degeneration, the Rd1 mouse (Figure S1) suggesting that
photoreceptor loss often produces a reactive gliosis.
Few cells in the INL with a bipolar morphology were positive
for GFP, but not for the Go protein, normally expressed by wild-
type bipolar cells (data not shown). We attempted to investigate
other markers, such as PKCa. However, a strong decrease of the
expression of this protein is observed in this model and renders co-
localization with GFP difficult (data not shown). Other works have
also described a reduction of PKCa during the retinal degener-
ation of other models[26], probably due to a lack of normal inputs
from the photoreceptors.
These results show that during the degenerating process the
diffusion capacity of the lentiviral vector pseudotyped with the
VSVG envelope is almost not changed. Nonetheless, we observed
that some Mu ¨ller cells can be targeted. Because a strong
remodeling of glial cells occurs, we were interested to evaluate
Figure 1. The OLM is altered after light damage (LD). (a) ZO-1 is homogeneously expressed along the OLM in untreated mouse (a, arrow),
whereas 36 hours after light damage, disruption of the protein labelling is apparent (b, arrows). Note also the reduced expression of ZO-1 after light
damage. The slices were processed simultaneously for the immuhistochemistry labelling and pictures were taken with the same exposure time
(700 ms). (a9,b 9) show the nuclear staining of the respective retinas. Note that the ONL is markedly reduced in the light-damaged retina (b9).
Representative pictures of wild-type mouse retina (c) and light damaged retina (d) subretinally injected with LV-VSVG-Rhop-GFP. Few photoreceptors
(green) were transduced in both cases. No significant differences were observed between groups (see text). The transduced area was confined to the
injection site. (c9 and d9) Merged picture of GFP expressing cells with DAPI staining. Calibration bar in (a): 50 mm (for a, a9,b and b9). Calibration bar in
(c): 100 mm (for c, c9, d and d9).
doi:10.1371/journal.pone.0023782.g001
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throughout the retina in 1.4, 3.3 and 5.4 month-old mice respectively (a, b, c, arrows), but the labelling changes with age. In Rho-/-
mice, ZO-1 distribution is normal at 1 month of age (d), starts to show few alterations at 2.4 months (e, arrows) and is often disrupted at 4.9 months (f,
arrows). (a9,b 9,c 9,d 9,e 9,f 9) represent the nuclei of the above pictures. Note the progressive photoreceptor loss in the Rho-/- mice (d9,e9,f9). INL: inner
nuclear layer, ONL: outer nuclear layer. All retina slices of this figure were processed simultaneously and pictures were taken with the same exposure
time (400 ms). Calibration bar in (a): 50 mm (for all pictures).
doi:10.1371/journal.pone.0023782.g002
Figure 3. Low photoreceptor transduction with the LV-VSVG-Rhop-GFP in the Rho-/- retina. Injections of the vector into 1.4 and 5.4
month old wild-type (WT) retinas transduce few photoreceptors (red, a, c). Similar results were observed in the 1 month-old Rho-/- mice (b), and the
transduction efficiency is even worse at 4.9 month (d). (a9,b 9,c 9,d 9) represent the nuclei (DAPI staining) of the above pictures. INL: inner nuclear layer,
ONL: outer nuclear layer. Calibration bar in (a) 100 mm (for a, a9, b and b9); calibration bar in (c): 50 mm (for c, c9, d and d9).
doi:10.1371/journal.pone.0023782.g003
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during retinal degeneration. To optimize the transduction of
Mu ¨ller cells, we changed the vector envelope by replacing VSVG
by the Mokola virus envelope. Additionally, we changed the
promoter for the CMV promoter, also shown to be active in
Mu ¨ller cells[27]. Indeed, previous results performed in the brain
have shown that Mokola-pseudotyped lentiviral vectors can
efficiently transduce glial cells[25,28]. Adult control and mid-
stage degeneration Rho-/- mice were injected with the LV-Mok-
CMV-GFP vector. In the wild-type animals, the neuroretina is
only transduced at the injection site and the expression is mainly
restricted to a large percentage of the RPE cells and encompasses
the size of the bleb performed during the injection (Figure 5a) as
previously described[1,29], thus very similar to the VSVG
pseudotyped LV. A large portion of the RPE layer is targeted
by the vector. By contrast in the Rho-/- retina, the behavior of the
LV-Mok is very different in comparison to LV-VSVG. The
Mokola vector transduces a large area of the neuroretina in the
Rho-/- and only few cells in the WT animal, 2366.5% (n=5) of
the retina surface versus 1.560.3% (n=4) respectively (P=0.014,
Figure 5c). In the diseased retina, in addition to the transduction of
RPE cells, almost all of the transduced cells have a Mu ¨ller cell
morphology (Figure 5d, f) and all of the targeted cells express
glutamine synthetase, an enzyme only expressed in this cell type
(Figure 5h and i). We estimated the percentage of Mu ¨ller cells
transduced by this vector and observed that 7967.2% (n=3) of
the glial cells express GFP. The extension of the transduced retina
area is comparable to the size of the RPE layer targeted by the
virus revealing the ability of the LV-Mok to target the glial cells of
the neuroretina in a diseased retina.
Discussion
The present study shows that the lentiviral vector may have
different capacity to transduce cells during the course of retinal
degeneration. Indeed, retinal remodelling during the disease
modifies the tropism of the LVs. Consequently, the use of different
envelopes and promoters allows to play with different targets in the
degenerating retina. Using specific Mokola-pseudotyped LV,
Mu ¨ller cells can be preferentially targeted during retinal
degeneration along with RPE cells.
During retinal degeneration, the disruption of ZO-1 labelling
integrity suggests that the OLM is altered rendering possible the
entry of entities into the retina that are normally blocked in the
healthy retina by this barrier. Indeed, ZO-1 is a major stabilization
actor of the OLM connexion. In the Rho-/- mice, previous studies
showed that the decreased expression of ZO-1 is also paralleled by
a decrease of b-catenin association which is normally bound to
ZO-1[20]. But the overall results were surprising in the late stage
Rho-/- mice. Very few photoreceptors express GFP when using the
LV with the Rhodopsin promoter suggesting that the vector diffuses
less in the degenerating retina. However, the use of the ubiquitous
promoter EFs shows that near the injection site some photore-
ceptors can be transduced suggesting that in the Rho-/- mice the
Rhodopsin promoter activity may change during the course of
retinal degeneration or that non-detectable cones can be
transduced. Even if some photoreceptors can be targeted with
the LV-EFs-GFP vector, the number of cells that can be
transduced remains very low. This limited photoreceptor trans-
duction is probably due to a change of OLM structure and glia
paralleling ZO-1 expression change.
Figure 4. The LV-VSVG-EFs-GFP transduces cells of the inner nuclear layer and photoreceptors in the degenerating retina. In control
animals (5.4 months), the vector transduces cells (green) in the neuroretina only at the injected area (a, b: GFP and DAPI staining). Note that RPE cells
are well transduced (a, b). (c) The extension of the transduced area in the neuroretina is small (left columns) both in wild-type and Rho-/- mice (n=5
for each group). The vector has a better efficacy on RPE cells (right columns). In 4.9 month-old Rho-/- mice, the vector diffuses into the retina and
targets cells with different morphologies in the INL (d, f, g, i) as well as in the ONL (g, h, i, arrows). DAPI staining of (d) and (g) are presented in (e or h).
(f) merged pictures of (d) and (e). (h) Immunolabelling for the Mu ¨ller glial protein GFAP (red). (i) Very rare GFP-positive cells were positive for GFAP
(red). INL: inner nuclear layer, ONL: outer nuclear layer. Calibration bar in (a): 100 mm (for a, b, d, e and f). Calibration bar in (g): 50 mm (for g, h and i).
doi:10.1371/journal.pone.0023782.g004
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GFAP expression was observed with many processes surrounding
the remaining photoreceptors (see Figure 4) suggesting a transfor-
mation of the OLM probably by reinforcing the barrier effect of the
Mu ¨ller cells endfeet. Previous studies have shown that during retinal
degeneration, the Mu ¨ller cells present a marked modification in
protein expression[17,21], beginning to express filament protein
such as GFAP and also vimentin that may change the structure
density of the cells. An interesting work has demonstrated that the
integration of primary fœtal transplanted retinal cells is drastically
reinforced when both vimentin and GFAP are missing in the Mu ¨ller
cells (GFAP-/-::Vimentin-/- mice), whereas a reduced migration is
seen when either GFAP or vimentin alone is suppressed[30]. Our
experiments suggest that at a later retinal degeneration stage, after
the alteration of the ZO-1 structure, gliosis may impair VSVG-
pseudotyped lentiviral vector diffusion.
In Rho-/- retinas, following the defect of ZO-1 expression, some
other components of the extracellular matrix may compensate for
this function loss. The ability of the vector to diffuse (or not) may
thus be a question of timing during the course of OLM
remodelling. CD44 or Neurocan are candidates of the extracel-
lular matrix (ECM) that may enhance the barrier effect. These
proteoaminoglycans were shown to impair the migration of
transplanted retinal progenitor cells from the subretinal space
towards the retina[23]. The Crumb protein was also shown to be
an important protein for the OLM barrier effect on transplanted
cell integration[22]. So far, the potential barrier influence of these
components of the ECM on viral particle diffusion is unknown and
merits to be investigated. Nonetheless, for certain approaches, the
opening of this barrier seems to have to be limited in time to
prevent retina cell alteration[31].
The lentiviral vector with the VSVG envelop was already shown to
target Mu ¨ller cells in the rat retina, when the vector contains the
GFAPpromoter[7].Surprisingly,thepresenceoftheCMVpromoter
does not allow expression of the reporter transgene in Mu ¨ller cells[7].
In this cited study, the LV-GFAPp-eGFP vector pseudotyped by the
VSVG envelope transduces a very large proportion of Mu ¨ller cells
(more than 90%) when subretinally injected at PN21 in normal and
diseased retina (the S334Ter+/- rat which bears a dominant
mutation in the Rhodopsin gene). The advantage of the LV-Mok
vector described in our study is totargetMu ¨llercellsonlyinadiseased
retina, even using a ubiquitous promoter.
Other vectors were developed to target the Mu ¨ller cells such as
Adenovirus-derived vectors. The Ad5/F37 largely diffuses in the
retina and transduces around 11% of the cells in the inner nuclear
layer where Mu ¨ller cells reside[32]. Using a directed evolution
approach to select vectors that efficiently transduce primate
astrocytes in vitro, Klimczak et al. identified that the AAV variant
ShH10 has a great capacity to infect Mu ¨ller cells in vivo when
injected into the vitreous[33]. This elegant study reveals that more
than 20% of the Mu ¨ller cells can be transduced by such delivery
way. This variant is close to the AA2/6 serotype, which also
specifically transduces activated Mu ¨ller glia cells (but with a lower
efficacy than the cited above serotype), when the transgene
expression is driven by the GFAP promoter[34]. The added-value
of these vectors and approach is to avoid deleterious side effects
Figure 5. In the degenerating Rho-/- retina, the LV-Mok-CMV-GFP preferentially transduces Mu ¨ller cells in an extended region of
the retina. In control animals (WT, 3.3 months), the vector targets cells (green) only at the injected area (a, b with DAPI). (c) The LV- Mok-CMV-GFP
vector transduces a large portion of the Rho-/- retina but not of the wild-type retina (compare blue columns). The extension of the transduction is
similar in the retina and the RPE layer and represents around 25–30% of the retina. In the 2.4 month-old Rho-/- retinas, the vector infects many cells
with a Mu ¨ller morphology (d, e, f, g with DAPI). The RPE cells are not present in this picture. (f) shows a magnification of (d) to better show the Mu ¨ller
cell morphology of the transduced cells. (g) another example of transduced cells in the Rho-/- retina where both RPE cells and cells with a Mu ¨ller cell
morphology (arrow) are targeted (the brightness of RPE labelling partially hides the Mu ¨ller cells). (h) many of the transduced cells express also
glutamine synthetase (GS, red), specific of Mu ¨ller cells. Few GS-positive cells do not express GFP (arrows). (i) The magnification of picture (h) reveals
that the great majority of glutamine synthetase-positive cells were transduced. Note that few cells show no green signal in the cell body (arrow). INL:
inner nuclear layer, ONL: outer nuclear layer, *: P=0.014. Calibration bar in (a): 100 mm (for a, b, d, e, g and h). Calibration bar in (f): represents 50 mm
for (f) and 54 mm for (i).
doi:10.1371/journal.pone.0023782.g005
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degenerating retina. However, the delivery efficiency needs to be
improved.
The use of the Mokola envelope redirects the LV targeting to a
large proportion of Mu ¨ller cells over an important distance
corresponding to the bleb area (this probably through the endfeet
which are in the vicinity of the RPE). This characteristic is seen only
in the degenerating retina. This extended area of glial cell
transduction mightbe interesting for using this vectorfor therapeutic
applications. Indeed, targeting Mu ¨ller cells may serve to deliver
neurotrophic substances to support the survival of photoreceptor
cells during retinal degeneration. In the context of such strategy so
far, gene transfer approaches mainly aim to target the RPE cells.
However, a constant fluid flux from the vitreous towards the choroid
exists. In consequence, the trophic factor engineered in RPE cells is
secreted against this flux which could limit its efficacy. In contrast, a
trophic factor released by Mu ¨ller cells may better reach the
photoreceptors. Very interesting works recently demonstrated the
usefulness of this approach in two different models of retinal
degeneration using AAV vectors[35,36]. Neurotrophic factor
delivery may also be used in combination with gene replacement
strategy. In addition, in severe forms of photoreceptor loss such as
early forms of LCA and RP, such gene transfer can support the
survival of the photoreceptors until the benefit of the transgene
replacement occurs[37]. Other applications of our results could be
the control of the Mu ¨ller cell structure to allow a better integration of
transplanted retinal cells derived from stem cells, for instance by
reducing gliosis, which can be achieved by siRNA transfer[38].
Most of the studies on vector tropism were undertaken in
normal retinas or at an early stage of retinal degeneration and little
is known concerning the ability of the vectors to transduce retinal
cells at advanced stages of retinal degeneration. We show that the
Mokola vector can efficiently transduce Mu ¨ller cells in a diseased
retina while it had been described as a very specific tool to target
RPE cells in a normal rat retina[1,29]. Similarly, the Rhodopsin
promoter surprisingly appeared less efficient than the EFs
promoter to drive transgene expression in photoreceptors in a
degeneration context, this will probably be true for any vector
used, i.e. LV, AAV or AdV. In this regard, the overall meaning of
our results underlines the importance of evaluating gene transfer
tools in the final context of use since the environment as well as the
target cells may be subjected to various modifications that will
impact on the transduction capacities.
Materials and Methods
Vector production
The EFS-GFPII transgene cassette was obtained by subcloning
hrGFPII (Agilent Technologies, Santa Clara, CA) in the Hlox-
EFS-GFP backbone[5] after discarding the GFP gene. The Rho-
GFP transgene plasmid was described in Kostic et al.[5].
Production of LV-VSV-G–Rhop or EFS-GFPII by cotransfection
in 293T cells was performed as described in Bemelmans et al.[9].
The CMV-GFP cassette is described in[39]. Production of the
Mokola-pseudotyped LV-CMV-GFP was also performed by triple
transfection but using the Mokola plasmid[29] instead of the
pMD.G encoding the VSV-G protein. Quantifications of the
vector stocks were measured using the RETRO-TEK HIV-1 p24
Antigen ELISA kit (ZeptoMetrixCorporation, Buffalo, NY USA)
according to the manufacturer’s instructions.
Ethic statement
The animals were handled in accordance with the statement of
the "Animals in Research Committee" of the Association for
Research in Vision and Ophthalmology, and protocols followed
the national regulations (OFEV) and were approved by the local
institutional committee, the ‘‘Service de la consommation et des
affaires ve ´te ´rinaires du canton de Vaud’’ (autorisation
VD#1367.3).
Animal procedure
Rhodopsin knockout mice were derived from Rpe65-/-::Rho-/-
mice (Professor C. Grimm, University of Zu ¨ r i c h )a n dc r o s s e di nt h e
C57/Bl6 background. Each eye was subretinally injected with 150 ng
of vector in 2 microliters as described previously[9]. For immunohis-
tochemical procedures, the eyes were collected 1 week after the
injection, cauterized to indicate the orientation, fixed in 4%
paraformaldehyde, washed in PBS and then immerged in 30%
sucrose overnight. The eye is then embedded in albumin from hen egg
white (Fluka, Buchs, Switzerland) and cut into 14 mm cryostat sections.
Immunohistochemistry
For immunohistochemistry sections were incubated with the first
antibody overnight at 4uC in PBS containing 0.2% TritonX-100
and 10% normal horse serum. Sections were then washed in PBS
and incubated with the secondary antibody at 37uC for 1 hour. The
following primary antibodies were used: goat polyclonal anti-GFP
for eyes injected with LV-Rho-GFP (1/3000, Abcam), mouse
monoclonal anti-ZO-1 (ZO1-1A12, 1/60, Invitrogen, Camarillo,
CA) and rabbit polyclonal anti-glutamine synthetase (1/5000,
Sigma-Aldrich). For visualization, fluorescence-labelled secondary
antibodies (Alexa-488 and Alexa-633; Molecular Probes) were used.
Sections were counterstained with DAPI (Molecular Probes) and
mounted under coverslips with Mowiol 4–88 Reagent (VWR
International AG, Lucerne, Switzerland).
Quantification and statistical analysis
To evaluate the potency of the vectors to spread in the
subretinal space and in the retina, we measured near the injection
site the maximum length of the area comprising transduced cells.
The length of transduced RPE estimates the size of the injection
bleb while the length of transduced retina cells reflects its efficiency
to penetrate through the retinal layers. The values were expressed
as percentage of total retinal length. If the size of both transduced
RPE and transduced retina are similar, the tested vector shows the
capacity to transduce retinal cells. If the size of GFP-positive retina
is much smaller than the GFP-positive RPE region, the tested
vector penetrated into the retina only because of the injury
produced by the needle.
For statistical analyses, groups were compared by an unpaired
Student T test using the Excel software (Microsoft, WA).
Supporting Information
Figure S1 Gliosis occurs during retinal degeneration of
the Rd1 mouse retina. The mouse bears a mutation in the
Pde6b gene leading to phototransduction inhibition and photore-
ceptor loss. At P12, GFAP (red) expression is mainly detected in
the inner part of the retina. At p15, the gliosis increases when
several layers of photoreceptors were already lost (compare the
ONL size with WT retina). Magnification: 200x.
(PDF)
Author Contributions
Conceived and designed the experiments: YA CK. Performed the
experiments: M. Calame MT DW SP M. Cachaferiro KS. Analyzed the
data: M. Calame YA. Contributed reagents/materials/analysis tools: CS.
Wrote the paper: YA M. Calame CK SP CS.
Lentiviral Tropism in Diseased Retinas
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23782References
1. Auricchio A, Kobinger G, Anand V, Hildinger M, O’Connor E, et al. (2001)
Exchange of surface proteins impacts on viral vector cellular specificity and
transduction characteristics: the retina as a model. Hum Mol Genet 10:
3075–3081.
2. Weber M, Rabinowitz J, Provost N, Conrath H, Folliot S, et al. (2003)
Recombinant adeno-associated virus serotype 4 mediates unique and exclusive
long-term transduction of retinal pigmented epithelium in rat, dog, and
nonhuman primate after subretinal delivery. Mol Ther 7: 774–781.
3. Dinculescu A, Glushakova L, Min SH, Hauswirth WW (2005) Adeno-associated
virus-vectored gene therapy for retinal disease. Hum Gene Ther 16: 649–663.
4. Surace EM, Auricchio A (2008) Versatility of AAV vectors for retinal gene
transfer. Vision Res 48: 353–359.
5. Kostic C, Chiodini F, Salmon P, Wiznerowicz M, Deglon N, et al. (2003)
Activity analysis of housekeeping promoters using self-inactivating lentiviral
vector delivery into the mouse retina. Gene Ther 10: 818–821.
6. Miyoshi H, Takahashi M, Gage FH, Verma IM (1997) Stable and efficient gene
transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad
Sci U S A 94: 10319–10323.
7. Greenberg KP, Geller SF, Schaffer DV, Flannery JG (2007) Targeted transgene
expression in muller glia of normal and diseased retinas using lentiviral vectors.
Invest Ophthalmol Vis Sci 48: 1844–1852.
8. Buch PK, Bainbridge JW, Ali RR (2008) AAV-mediated gene therapy for retinal
disorders: from mouse to man. Gene Ther 15: 849–857.
9. Bemelmans AP, Kostic C, Crippa SV, Hauswirth WW, Lem J, et al. (2006)
Lentiviral gene transfer of RPE65 rescues survival and function of cones in a
mouse model of Leber congenital amaurosis. PLoS Med 3: e347.
10. Tschernutter M, Schlichtenbrede FC, Howe S, Balaggan KS, Munro PM, et al.
(2005) Long-term preservation of retinal function in the RCS rat model of
retinitis pigmentosa following lentivirus-mediated gene therapy. Gene Ther 12:
694–701.
11. Yanez-Munoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, et al. (2006)
Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 12:
348–353.
12. Van Adel BA, Kostic C, Deglon N, Ball AK, Arsenijevic Y (2003) Delivery of
Ciliary Neurotrophic Factor via Lentiviral-Mediated Transfer Protects Axoto-
mized Retinal Ganglion Cells for an Extended Period of Time. Hum Gene Ther
14: 103–115.
13. Takahashi M, Miyoshi H, Verma IM, Gage FH (1999) Rescue from
photoreceptor degeneration in the rd mouse by human immunodeficiency virus
vector-mediated gene transfer. J Virol 73: 7812–7816.
14. Gruter O, Kostic C, Crippa SV, Perez MT, Zografos L, et al. (2005) Lentiviral
vector-mediated gene transfer in adult mouse photoreceptors is impaired by the
presence of a physical barrier. Gene Ther.
15. Balaggan KS, Binley K, Esapa M, Iqball S, Askham Z, et al. (2006) Stable and
efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors.
J Gene Med 8: 275–285.
16. Kong J, Kim SR, Binley K, Pata I, Doi K, et al. (2008) Correction of the disease
phenotype in the mouse model of Stargardt disease by lentiviral gene therapy.
Gene Ther 15: 1311–1320.
17. Jones BW, Watt CB, Frederick JM, Baehr W, Chen CK, et al. (2003) Retinal
remodeling triggered by photoreceptor degenerations. J Comp Neurol 464:
1–16.
18. Strettoi E, Porciatti V, Falsini B, Pignatelli V, Rossi C (2002) Morphological and
functional abnormalities in the inner retina of the rd/rd mouse. J Neurosci 22:
5492–5504.
19. Campbell M, Humphries M, Kennan A, Kenna P, Humphries P, et al. (2006)
Aberrant retinal tight junction and adherens junction protein expression in an
animal model of autosomal dominant Retinitis pigmentosa: the Rho(-/-) mouse.
Exp Eye Res 83: 484–492.
20. Campbell M, Humphries M, Kenna P, Humphries P, Brankin B (2007) Altered
expression and interaction of adherens junction proteins in the developing OLM
of the Rho(-/-) mouse. Exp Eye Res 85: 714–720.
21. Marc RE, Jones BW, Watt CB, Strettoi E (2003) Neural remodeling in retinal
degeneration. Prog Retin Eye Res 22: 607–655.
22. Pearson RA, Barber AC, West EL, MacLaren RE, Duran Y, et al. (2010)
Targeted disruption of outer limiting membrane junctional proteins (Crb1 and
ZO-1) increases integration of transplanted photoreceptor precursors into the
adult wild-type and degenerating retina. Cell Transplant 19: 487–503.
23. Tucker B, Klassen H, Yang L, Chen DF, Young MJ (2008) Elevated MMP
Expression in the MRL Mouse Retina Creates a Permissive Environment for
Retinal Regeneration. Invest Ophthalmol Vis Sci 49: 1686–1695.
24. Kolstad KD, Dalkara D, Guerin K, Visel M, Hoffmann N, et al. (2010) Changes
in adeno-associated virus-mediated gene delivery in retinal degeneration. Hum
Gene Ther 21: 571–578.
25. Pertusa M, Garcia-Matas S, Mammeri H, Adell A, Rodrigo T, et al. (2008)
Expression of GDNF transgene in astrocytes improves cognitive deficits in aged
rats. Neurobiol Aging 29: 1366–1379.
26. Pignatelli V, Cepko CL, Strettoi E (2004) Inner retinal abnormalities in a mouse
model of Leber’s congenital amaurosis. J Comp Neurol 469: 351–359.
27. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM (1998) Development
of a self-inactivating lentivirus vector. J Virol 72: 8150–8157.
28. Colin A, Faideau M, Dufour N, Auregan G, Hassig R, et al. (2009) Engineered
lentiviral vector targeting astrocytes in vivo. Glia 57: 667–679.
29. Bemelmans AP, Bonnel S, Houhou L, Dufour N, Nandrot E, et al. (2005)
Retinal cell type expression specificity of HIV-1-derived gene transfer vectors
upon subretinal injection in the adult rat: influence of pseudotyping and
promoter. J Gene Med 7: 1367–1374.
30. Kinouchi R, Takeda M, Yang L, Wilhelmsson U, Lundkvist A, et al. (2003)
Robust neural integration from retinal transplants in mice deficient in GFAP
and vimentin. Nat Neurosci 6: 863–868.
31. West EL, Pearson RA, Tschernutter M, Sowden JC, MacLaren RE, et al. (2008)
Pharmacological disruption of the outer limiting membrane leads to increased
retinal integration of transplanted photoreceptor precursors. Exp Eye Res 86:
601–611.
32. Sweigard JH, Cashman SM, Kumar-Singh R (2010) Adenovirus vectors
targeting distinct cell types in the retina. Invest Ophthalmol. Vis Sci 51:
2219–2228.
33. Klimczak RR, Koerber JT, Dalkara D, Flannery JG, Schaffer DV (2009) A
novel adeno-associated viral variant for efficient and selective intravitreal
transduction of rat Muller cells. PLoS One 4: e7467.
34. Aartsen WM, van Cleef KW, Pellissier LP, Hoek RM, Vos RM, et al. (2010)
GFAP-driven GFP expression in activated mouse Muller glial cells aligning
retinal blood vessels following intravitreal injection of AAV2/6 vectors. PLoS
One 5.
35. Dalkara D, Kolstad KD, Guerin KI, Hoffmann NV, Visel M, et al. (2011) AAV
Mediated GDNF Secretion From Retinal Glia Slows Down Retinal Degener-
ation in a Rat Model of Retinitis Pigmentosa. Mol Ther.
36. Dorrell MI, Aguilar E, Jacobson R, Yanes O, Gariano R, et al. (2009)
Antioxidant or neurotrophic factor treatment preserves function in a mouse
model of neovascularization-associated oxidative stress. J Clin Invest 119:
611–623.
37. Buch PK, MacLaren RE, Duran Y, Balaggan KS, MacNeil A, et al. (2006) In
contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression
enhances gene replacement therapy in rodent models of retinal degeneration.
Mol Ther 14: 700–709.
38. Desclaux M, Teigell M, Amar L, Vogel R, Gimenez YR, et al. (2009) A novel
and efficient gene transfer strategy reduces glial reactivity and improves neuronal
survival and axonal growth in vitro. PLoS One 4: e6227.
39. Philippe S, Sarkis C, Barkats M, Mammeri H, Ladroue C, et al. (2006) Lentiviral
vectors with a defective integrase allow efficient and sustained transgene
expression in vitro and in vivo. Proc Natl Acad Sci U S A 103: 17684–17689.
Lentiviral Tropism in Diseased Retinas
PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23782